Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8491551 | 0.80 | PTK2 (0.51) | ALDH1A1LMNATP53MAPTKMT2A | |
| SCHEMBL8492114 | 0.78 | NPC1 (0.50) | TP53KMT2AMEN1 | |
| SCHEMBL8495201 | 0.77 | RAB9A (0.51) | MAPTKMT2AGAAPOLBMEN1 | |
| SCHEMBL6496159 | 0.77 | NPC1 (0.53) | ALDH1A1LMNAMAPTKMT2APOLB | |
| SCHEMBL29165008 | 0.76 | HDAC1 (0.48) | ALDH1A1LMNAMAPT | |
| SCHEMBL30822692 | 0.76 | HDAC1 (0.48) | ALDH1A1LMNAMAPT | |
| SCHEMBL8493684 | 0.73 | RAB9A (0.53) | ALDH1A1TP53MAPTATMKMT2A | |
| SCHEMBL6483601 | 0.73 | SMARCA2 (0.44) | ALDH1A1LMNATP53MAPTATM | |
| SCHEMBL6483433 | 0.73 | SMN1; SMN2 (0.51) | ALDH1A1LMNATP53MAPTKMT2A | |
| SCHEMBL6484255 | 0.72 | RAB9A (0.52) | ALDH1A1LMNAMAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2004-07-01 | — | — | US | claimed |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2003-01-16 | — | — | US | claimed |
| US-6455566-B1 | Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents | WYETH | 2002-09-24 | — | — | US | claimed |
| WO-1999011638-A1 | SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | claimed |
| US-6936630-B2 | Substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2004-07-01 | — | — | US | disclosed |
| US-6686476-B2 | ANTICHOILESTEROL AGENTS; CARDIOVASCULAR DISORDERS | WYETH | 2004-02-03 | — | — | US | disclosed |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2003-01-16 | — | — | US | disclosed |
| US-6455566-B1 | Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents | WYETH | 2002-09-24 | — | — | US | disclosed |
| WO-1999011638-A1 | SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | ALDH1A1 740/4885LMNA 4357/4885TP53 4665/4885 |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | ALDH1A1 740/4885LMNA 4357/4885TP53 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.